News | June 28, 2022
Balaxi Pharmaceuticals' Hyderabad factory to be operational by March 2024
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Bringing next-gen cannabinoid therapeutics to cancer patients
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
The new program includes upstream and downstream process development and large-scale GMP production.
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
Facility features LED lighting, solar panels, automation and innovative temperature-controlled systems to maximize efficiency and minimize environmental impact
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
Subscribe To Our Newsletter & Stay Updated
